Protein Summary
Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality. [provided by RefSeq, Jul 2008]
- ENST00000264692
- ENSP00000264692
- ENSG00000088926
- ENST00000403665
- ENSP00000384957
- FXI
- PTA
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 0.92 | ||
biological term | 0.84 | ||
molecular function | 0.73 | ||
gene perturbation | 0.63 | ||
disease | 0.6 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 751.9 (req: < 5)
Gene RIFs: 166 (req: <= 3)
Antibodies: 431 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 751.9 (req: >= 5)
Gene RIFs: 166 (req: > 3)
Antibodies: 431 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 742
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0